---
pmid: '20534451'
title: Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer
  progression [corrected].
authors:
- Wang Y
- Kelber JA
- Tran Cao HS
- Cantin GT
- Lin R
- Wang W
- Kaushal S
- Bristow JM
- Edgington TS
- Hoffman RM
- Bouvet M
- Yates JR 3rd
- Klemke RL
journal: Proc Natl Acad Sci U S A
year: '2010'
full_text_available: false
pmcid: PMC2890752
doi: 10.1073/pnas.0914776107
---

# Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].
**Authors:** Wang Y, Kelber JA, Tran Cao HS, Cantin GT, Lin R, Wang W, Kaushal S, Bristow JM, Edgington TS, Hoffman RM, Bouvet M, Yates JR 3rd, Klemke RL
**Journal:** Proc Natl Acad Sci U S A (2010)
**DOI:** [10.1073/pnas.0914776107](https://doi.org/10.1073/pnas.0914776107)
**PMC:** [PMC2890752](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890752/)

## Abstract

1. Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10920-5. doi: 
10.1073/pnas.0914776107. Epub 2010 Jun 1.

Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer 
progression [corrected].

Wang Y(1), Kelber JA, Tran Cao HS, Cantin GT, Lin R, Wang W, Kaushal S, Bristow 
JM, Edgington TS, Hoffman RM, Bouvet M, Yates JR 3rd, Klemke RL.

Author information:
(1)Department of Pathology, Moores Cancer Center, University of California, La 
Jolla, CA 92093, USA.

Erratum in
    Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13556.

Regulation of the actin-myosin cytoskeleton plays a central role in cell 
migration and cancer progression. Here, we report the discovery of a 
cytoskeleton-associated kinase, pseudopodium-enriched atypical kinase 1 (PEAK1). 
PEAK1 is a 190-kDa nonreceptor tyrosine kinase that localizes to actin filaments 
and focal adhesions. PEAK1 undergoes Src-induced tyrosine phosphorylation, 
regulates the p130Cas-Crk-paxillin and Erk signaling pathways, and operates 
downstream of integrin and epidermal growth factor receptors (EGFR) to control 
cell spreading, migration, and proliferation. Perturbation of PEAK1 levels in 
cancer cells alters anchorage-independent growth and tumor progression in mice. 
Notably, primary and metastatic samples from colon cancer patients display 
amplified PEAK1 levels in 81% of the cases. Our findings indicate that PEAK1 is 
an important cytoskeletal regulatory kinase and possible target for anticancer 
therapy.

DOI: 10.1073/pnas.0914776107
PMCID: PMC2890752
PMID: 20534451 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no conflict of interest.
